RP1 Combination Shows Response, Safety in Advanced Melanoma
Source: Targeted Oncology, January 2025
Vusolimogene oderparepvec plus nivolumab showed responses and a favorable safety profile in advanced melanoma post-anti–PD-1 therapy, per phase 2 IGNYTE trial data.
THE ONCOLYTIC IMMUNOTHERAPY vusolimogene oderparepvec (RP1) plus nivolumab (Opdivo) led to responses and had a favorable safety profile in patients with advanced melanoma whose disease progressed on or after prior antiPD-1 therapy, according to data from the phase 2 IGNYTE trial (NCT03767348).
Findings presented at the 2024 Society for Immunotherapy of Cancer Annual Meeting demonstrated that at a median follow-up of 15.4 months (range, 0.5-47.6), patients treated with RP1 plus nivolumab (n = 140) achieved a confirmed overall response rate (ORR) of 33.6% (95% CI, 25.8%-42.0%) per modified RECIST (mRECIST) 1.1 criteria by blinded independent central review (BICR) assessment. This comprised a complete response (CR) rate of 15.0% and a partial response (PR) rate of 18.6%; the stable disease (SD) and progressive disease (PD) rates were 29.3% and 30.7%, respectively.